

# Efficacy of physiotherapy including a craniocervical training programme for tension-type headache; a randomized clinical trial

H van Ettekovén<sup>1</sup> & C Lucas<sup>2</sup>

<sup>1</sup>Centre for Physiotherapy and Manual Therapy, Amstelveen and <sup>2</sup>Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands

## Cephalalgia

van Ettekovén H & Lucas C. Efficacy of physiotherapy including a craniocervical training programme for tension-type headache; a randomized clinical trial. *Cephalalgia* 2006; 26:983–991. London. ISSN 0333-1024

We conducted a multicentre, randomized controlled trial with blinded outcome assessment. The treatment period was 6 weeks with follow-up assessment immediately thereafter and after 6 months. The objective was to determine the effectiveness of a craniocervical training programme combined with physiotherapy for tension-type headache. Eighty-one participants meeting the diagnostic criteria for tension-type headache were randomly assigned to an exercise group (physiotherapy and an additional craniocervical training programme) and a control group (physiotherapy alone). The primary outcome measure was headache frequency. Secondary outcomes included headache intensity and duration, Quality of Life (SF-36) and the Multidimensional Headache Locus of Control scale (MHLC). At 6 months' follow-up, the craniocervical training group showed significantly reduced headache frequency, intensity and duration ( $P < 0.001$  for all). Effect sizes were large and clinically relevant. Loss to follow-up amounted to 3.7%. Physiotherapy including craniocervical training reduces symptoms of tension-type headache significantly over a prolonged time frame. □ Craniocervical training, physiotherapy, tension-type headache

J. W. van Ettekovén MSc, University of Amsterdam, Department of Clinical Epidemiology and Biostatistics, PO Box 22660, 1100 DD Amsterdam, the Netherlands. Tel. +31 2 0641 4543, +31 6 2053 0847, fax +31 2 0640 6388, e-mail [hansvettokoven@wanadoo.nl](mailto:hansvettokoven@wanadoo.nl)

Received 23 November 2005, accepted 29 January 2006

## Introduction

Tension-type headache is the most prevalent headache type. Almost 80% of the total population will experience a tension-type headache at some time. Headache is one of the 10 major complaints of patients seen in primary care practices and 47% of all headaches are tension-type headaches (1). 'Tension-type' labels a headache classification developed in 1988 by the International Headache Society (IHS). It can be divided into an episodic and a chronic version (2) and is commonly more experienced by women (female:male ratio 5 : 4) (3).

Because of its high prevalence—1-year prevalence in women 86% and in men 63% (4)—and its wide spectrum of disability, tension-type headache has a greater socioeconomic impact than any other

headache type (5). In spite of this, only 15% of people with tension-type headache seek medical attention (2) and 60% of those reporting severe headaches use only 'over-the-counter medication', standing a chance of analgesic rebound (6). Instead of self-management, a therapeutic approach, incorporating both non-pharmacological and pharmacological intervention, shows a success rate of >90% in patients with tension-type headache (7–9).

The specific cause of tension-type headache is unknown, but is most likely multifactorial (10–19), as adequately described by Olesen's vascular-myogenic-supraspinal model (20).

Until now, no previous trial has investigated the effect of craniocervical training in tension-type headache, dealing with specific deficits in muscle control of the cervicospinal part of the neck (21, 22). This

randomized, controlled trial assessed the short- and long-term effects of two approaches to tension-type headache: standard physiotherapy including a craniocervical training programme (CTP) in order to re-educate muscle control of the cervicospinal region (CTP group) and standard physiotherapy alone (control group) (23–25).

## Methods

### *Design*

The study was a prospective, multicentre, randomized controlled trial with blinded outcome assessment. Allocation was by means of a computerized randomized block design with stratification for version of tension-type headache (episodic vs. chronic), sex and treatment centre (one of the seven participating trial centres).

Based on sample size calculation with a two-sided  $\alpha$  of 0.05 and a power of 0.80, 80 patients had to be included to detect a 60% reduction of headache frequency in the intervention group, such a treatment effect being considered clinically relevant (26). Informed consent was obtained before randomization. The procedures followed were in accordance with the ethical standards of the responsible committees on human experimentation and with the Helsinki Declaration.

### *Participants*

Eligible patients were referred by general practitioners, after which they were screened on inclusion and exclusion criteria in one of the seven participating primary healthcare centres in the area of Amsterdam, the Netherlands. Those who fulfilled the symptomatic criteria underwent physical examination of the cervical spine including three function tests with relevance to the prescribed exercises of the intervention group.

The inclusion criteria followed the IHS classification for tension-type headache. The episodic version is defined as recurrent episodes of headache lasting minutes to days and <15 days per month. Pain quality is typically 'pressing' or 'tightening', of mild to moderate intensity, bilateral in location and not worsening during routine physical activity. Nausea and vomiting are absent, but photophobia or phonophobia may occur (2). The chronic version differs from the episodic since headache is present for at least 15 days per month, while in addition to photophobia or phonophobia, nausea may occur (2). During the trial period, the IHS classification was

revised (ICHD-II). However, the diagnostic criteria for tension-type headache were unchanged and therefore the revised classification did not interfere with the inclusion criteria of this study. Exclusion criteria specified the other headache types as described in the ICHD-II classification. Moreover, the presence of more than one type of headache in addition to tension-type headache, cervical function problems and previous physiotherapy treatment for tension-type headache during the last 6 months were excluded.

### *Interventions*

Physiotherapy consisted of a threefold approach: conventional Western massage techniques, oscillation techniques and instruction on postural correction. Conventional massage techniques included the following modes: 'effleurage' (stroking), 'petrissage' (kneading) and 'friction' (deep pressure). Mode and intensity were determined by the physiotherapist in accordance with the diagnosis and the patient's condition as a clinical routine. Oscillation techniques included the use of low-velocity, passive cervical joint mobilization, in which the cervical segments are rhythmically moved following a regimen described by Maitland (27). The two approaches described above are intended to reduce pain and musculotendinous tension.

Instruction on postural correction originates with the worst postural position of craniocervical extension (anteversion) of the head, cervicothoracic flexion, protraction of the shoulders and increased thoracic kyphosis and flattened lumbar lordosis while sitting. The physiotherapist instructs patients to correct these postural abnormalities through craniocervical flexion (retroversion) and cervicothoracic extension, retraction of the shoulders, extension of the thoracic spine and normalization of lumbar lordosis.

The craniocervical training programme was a new developed programme using low-load endurance exercises in order to train and/or to regain muscle control of the cervicospinal and craniocervical regions (28). To address the impairment in neck flexor synergy found in cervicogenic headache and other neck pain disorders (29, 30), craniocervical flexion exercises were performed, using a latex band (Thera-Band®, Resistive Exercise Systems; Hygenic Corporation, Akron, OH, USA blue colour-coded level of progressive resistance). The 150-cm latex band was used as a circular band, with one side positioned at the craniocervical region of the patient's neck and the other side fixed somewhat above the

horizontal. The resistance of the band was used in such a way that it facilitated the longus colli muscles (31). Exercises were performed in a sitting position with a natural lumbar lordosis, under slight scapular retraction and adduction and slightly elongating the cervical spine. Participants were instructed to perform a slow and controlled craniocervical flexion over various ranges of motion, resulting in various resistances, with various speeds using isometric contractions in various positions (Fig. 1a,b).

This craniocervical low-load training regimen was also incorporated in postural correction exercises. The duration of the CTP part of the treatment session did not exceed 15 min. During the intervention period, the participants were instructed to practice this CTP at home twice a day for 10 min per session. Using a daily diary, changes in headache frequency, intensity, duration and medication intake were monitored and compliance was controlled. After the treatment period the participants were instructed to continue the craniocervical training at home with a frequency according to their complaints, but at least

twice a week. Preceding the start of the trial, 20 experienced senior physiotherapists in the seven participating treatment centres were explicitly trained to execute the protocolled treatments.


#### Measurement instruments

Pain was assessed using a Numerical Rating Scale (NRS), an 11-item scale, with 0 representing no pain and 10 representing pain as bad as it could be, depicted on a horizontal line. Subjects were asked to mark the number that best represented the current level of pain they were experiencing. Various formats of the NRS (11-point levels of measure, 21-point levels of measure and 101-point numerical rating scale) have provided reliable data with coefficients  $>0.99$  (32). The validity and reliability of the NRS to measure pain in patients experiencing pain of acute and chronic origin have been demonstrated (33–36).


The Short-Form General Health Survey (SF-36) was used to assess health-related quality of life. The SF-36 is a generic 36-item self-administered survey that measures eight health domains: physical functioning (PF), social functioning (SF), role limitations due to physical health (RP), role limitations due to mental health (MH), general health (GH), emotional well-being (RE), vitality (VT) and bodily pain (BP) and two summary scores, physical component summary (PCS) and mental component summary (MCS). Three scales (PF, RP, BP) correlate most highly with the physical component and contribute most to the scoring of the PCS measure. The mental component correlates most highly with the MH, RE, and SF scales, which also contribute most to the scoring of the MCS measure. Three of the scales (VT, GH, SF) have noteworthy correlations with both components. The health domains described in the SF-36 range in score from 0 to 100, with higher scores indicating higher levels of functioning or better health. The reliability of the SF-36 has been estimated using both internal consistency and test-retest methods. With rare exceptions, published reliability statistics have exceeded the minimum required level of 0.70 recommended for measures used in group comparisons and most have exceeded 0.80. Validity studies generally support the intended objective of high and low SF-36 scores as documented in the original user's manuals (37–41).

The Multidimensional Health Locus of Control (MHLC) scales have been developed as specific instruments for measuring locus of control in the healthcare field. The MHLC scales used are moderately reliable; Cronbach alphas range from 0.60 to 0.75 and test-retest reliability coefficients from 0.60

(a)



(b)



**Figure 1** (a) Starting position in craniocervical extension (anteversion). (b) Final position with craniocervical flexion (retroversion).

to 0.70. Convergent validity has been calculated at  $r = 0.62-0.73$  (42, 43).

The MHLC used in this trial was specified for headache (Multidimensional Headache Locus of Control) and was examined to determine whether the patient's health beliefs, specifically about the control over one's headache, were influenced by the interventions.

### Statistical analysis

Baseline characteristics were summarized with descriptive statistics (Table 1). Furthermore, between-group analyses were performed using Mann-Whitney *U*-tests at end-point and at 6-month follow-up. Within-group analyses were performed using the Wilcoxon signed ranks test at end-point and at the 6-month follow-up. Spearman's rank correlation coefficients were calculated to examine the correlation between the Headache Locus of Control and the primary and secondary outcome measures.

For all outcome measures effect sizes of mean differences (ES) were calculated by dividing the difference between the mean changes in the outcomes of the control group and the CTP group by the within-group standard deviation of the total group.

**Table 1** Comparability of intervention groups at baseline in headache characteristics, prognostic variables and outcome measures

	CTP ( <i>n</i> = 39)	Control ( <i>n</i> = 42)
Age, years	48.3 (18.39)	43.4 (15.68)
Gender, % female	79.5	83.3
Headache type		
ETTH	20	19
CTTH	19	23
Headache frequency, days/week	5.49 (1.70)	4.86 (1.79)
Headache intensity, NRS 0-10	5.72 (1.43)	5.86 (1.84)
Headache duration, h/day	8.1 (4.98)	8 (5.0)
Medication, WDD	1.13 (1.44)	0.98 (1.09)
SF-36, PCS	46.45 (9.17)	41.71 (8.04)
SF-36, MCS	49.87 (7.73)	40.85 (11.12)
MHLC, internal	22.26 (5.38)	21.45 (5.24)
MHLC, external	26.33 (4.40)	25.43 (5.65)
MHLC, chance	23.87 (5.60)	23.95 (4.73)

Data are expressed in frequencies or means ( $\pm$ SD).

CTP, Craniocervical training group; ETTH, episodic tension-type headache; CTTH, chronic tension-type headache; NRS, numeric rating score; WDD, weekly dose expressed in days; SF-36, Short-Form 36; PCS, physical component summary; MCS, mental component summary; MHLC, Multidimensional Headache Locus of Control.

$$\frac{\bar{X}_{Control} - \bar{X}_{CTP}}{\lambda(Control + CTP)}$$

Effect sizes were considered small (0.2), medium (0.5) or large (0.8) (44). All analyses were done with SPSS 12.0 (SPSS Inc., Chicago, IL, USA) according to the intention-to-treat principle.

### Results

Of the 81 participants who entered the trial group, 38 in the CTP group and 42 in the control group received treatment and 3.7% were lost to follow-up. Participant flow and retention are summarized in Fig. 2. Randomization started in December 2003, recruitment was completed in April 2005 with follow-up scheduled to continue through October 2005. Baseline characteristics between the two groups were analogous (Table 1). No adverse events were reported in any group.

Mean changes in headache frequency, intensity and duration from baseline to end-point and follow-up are plotted in Fig. 3a-c. Wilcoxon signed ranks analyses showed that treatment within both the control group and the CTP group significantly reduced headache frequency, intensity and duration immediately after treatment. At this point, however, Mann-Whitney *U* analyses showed no significant difference between the control and CTP groups.


In the control group, however, from end-point to follow-up a significant increase in frequency, intensity and duration in headache occurred ( $P = 0.007$ ,  $P = 0.001$ ,  $P = 0.022$ , respectively). In contrast, the CTP group showed further reduction of headache frequency ( $P = 0.039$ ), intensity ( $P = 0.007$ ) and duration (NS).

At follow-up, the CTP group differed significantly from the control group in terms of headache frequency, intensity and duration ( $P = 0.0001$ ,  $P = 0.001$ ,  $P = 0.011$ , respectively) (Table 2).

Quality of life assessment in terms of mean changes in PCS and MCS showed significant improvement in PCS ( $P < 0.001$  for all) within groups and significant improvement between groups at follow-up in RE ( $P = 0.014$ ), MH ( $P = 0.05$ ), VT ( $P = 0.039$ ) and BP ( $P = 0.017$ ).

Calculation of treatment effect showed at a large effect size in both groups in terms of reduction of frequency, intensity and duration of the headache. The mental component summary showed a medium effect. Overall, at end-point, the CTP group showed the largest effect sizes.

The effectiveness of the two approaches was also investigated by examining the number of subjects



**Figure 2** Flow diagram of progression of participants through the trial.

who met the bench-mark cut-off point of a  $\geq 50\%$  reduction in headache frequency. In the control group 52% and 35% of the participants (at end-point and follow-up, respectively) met this criterion, in the CTP group the percentage amounted to 82% and 85% (at end-point and follow-up, respectively).

At end-point, the Wilcoxon signed ranks test showed up to 40% reduced medication intake within both treatment groups (control group  $P = 0.001$ ; CTP group  $P = 0.0001$ ). At follow-up, however, no significant reduction in the control group ( $P = 0.081$ ) was found; in contrast, the CTP group showed a 65% reduction ( $P = 0.0001$ ).


Within the CTP group, the Mann-Whitney  $U$ -test showed a significant difference between the two groups ( $P = 0.003$ ). Subgroup analysis showed a sig-

nificant reduction in favour of the chronic tension-type headache group ( $P < 0.0001$ ). Subgroup analysis for chronic tension-type headache (CTTH) and episodic tension-type headache (ETTH) by the Wilcoxon signed ranks test and the Mann-Whitney  $U$ -test showed that the within- and between-group headache frequency was in accordance with the unstratified analysis. Mean changes in headache frequency, intensity and duration for these subgroups are plotted in Fig. 4a-c.

Analysis of mean changes of the headache locus of control revealed no significant differences, either within or between the treatment groups. Spearman's rank correlation analysis showed no significant correlation between the headache locus of control and any outcome measures.

## Discussion

This trial supported evidence that physiotherapy combined with a specific therapeutic exercise regi-



**Figure 3** Mean changes in headache frequency (a), intensity (b) and duration (c) from baseline to end-point (week 6) and follow-up (month 6) per treatment group.  $\Delta$ , Control;  $\blacksquare$ , craniocervical training programme.

**Table 2** Mean changes (95% CI) in primary and secondary outcome measures at end-point (week 6) and follow-up (month 6)

	Week 6	P	Month 6	P
Frequency (days/week)	0.94 (0.71, 1.809)	0.061	1.95 (1.14, 2.76)	0.0001*
Intensity (num. rating scale)	-0.04 (-1.09, 1.01)	0.95	1.78 (0.82, 2.74)	0.001*
Duration (h/day)	-0.18 (-2.07, 1.70)	0.94	2.07 (0.12, 4.03)	0.011*
PCS	-0.16 (-4.42, 4.11)	0.62	-2.19 (-6.72, 2.35)	0.099
MCS	-2.77 (-6.64, 1.10)	0.14	-4.84 (-8.79, -0.90)	0.025*

PCS, Physical component summary; MCS, mental component summary.


\*Significant difference ( $P = 0.05$ ).

men was effective for tension-type headache. Although there was no significant difference between the two treatment groups immediately after treatment (end-point), at follow-up a significant and clinically relevant effect was shown in the CTP group.

As various research suggests (11, 13, 20, 22, 23, 45), afferent input produced by joint mobilization stimulates inhibitory systems at various levels in the spinal cord and modulates pain perception. It is most likely that the mechanisms of the treatment effect in this trial are to be found in the afferent input attributed to the mobilization and oscillation techniques of physiotherapy and to treatment by craniocervical exercises. This specific craniocervical training programme emphasized motor control rather than muscle strength and was carried out daily to twice a week in the post-treatment period. In this way, afferent input was continued in the craniocervical training group after end-point measurement. Possibly, this post-treatment period had a consolidating effect.

The CTP group showed a decrease in medication intake of 60%, which is more than 50% compared with the control group. The ETTH assessed in this study is synonymous with the frequent ETTH according to the ICHD-II classification. Participants suffering from infrequent ETTH were not included. Within the CTP group, a higher reduction of medication intake was shown in the CTHH group compared with the ETTH group.

The calculated effect size showed a large effect for all headache symptoms. A 50% reduction in headache frequency is regarded as clinically relevant by the IHS (26). In this study 85% of the participants in the CTP group showed a  $\geq 50\%$  reduction in headache frequency at follow-up, with 48% reporting 80–100% reduction at that time, indicating substantial clinical relevance. In contrast to what might be expected, the Headache Locus of Control was not influenced by the treatment effect and consequently could not be regarded as a predictive factor for any outcome measure.



**Figure 4** Mean changes in headache frequency (a), intensity (b) and duration (c) from baseline to end-point (week 6) and follow-up (month 6) per treatment group after stratification for type of headache.  $\Delta$ , Control episodic tension-type headache (ETTH);  $--\Delta--$ , control chronic tension-type headache (CTTH);  $--\blacksquare--$ , craniocervical training programme (CTP) CTTH;  $\blacksquare$ , CTP ETTH.

Since patients with tension-type headache very often use self-administered pain-relieving manoeuvres with only scant efficacy (46), the craniocervical training in this trial caters for this target group since the exercises are easy to perform, take little time and are effective. Considering the fact that reduction of headache frequency, intensity and duration continues after 6 months, a follow-up study including a longer time frame should be conducted to determine the efficacy of craniocervical exercises as a potential stand-alone treatment over a longer period of time.

A substantially longer follow-up will also emphasize the aspect of self-management of craniocervical training and might eventually detect a change in the Headache Locus of Control. The question arises whether the underlying mechanisms of craniocervical training reflect modulation of pain perception through increased afferent input, or the effect on craniocervical posture resulting in reduction of cervicospinal muscle tone. In other words: is it the action, or is it the posture? No answer can be provided from this trial, but the results underline the necessity for researching multimechanisms to explain pain reduction by this physiotherapeutic treatment. Trials of non-invasive physical therapies for tension-type headache have been criticized for poor methodological quality (47–49). Reviewers' recommendations suggest the necessity of further research, using rigorous scientific methods. We tried to fulfil this condition by following the CONSORT guidelines for randomized clinical trials; subject selection was based on validated criteria for tension-type headache, randomization was computerized and evaluation was performed through blinded data assessment. The statistical power was adequate to detect the hypothetical effects and loss to follow-up evaluation was low (3.7%). The nature of the intervention precluded the necessity for any blind condition on participants or therapists (open label trial).

In conclusion, this trial has shown that physiotherapy including a craniocervical training programme is effective in the management of chronic and episodic tension-type headache over a prolonged time frame.

## References

- 1 A study of headache in North American Primary Care: report from the Ambulatory Sentinel Practice. Network J R Coll General Pract 1987; 37:400–3.
- 2 Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Suppl. 7):1–96.
- 3 Friedman AP, de Sola Pool N, von Storch TJ. Tension headache. JAMA 1953; 151:174–7.
- 4 Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population: a prevalence study. J Clin Epidemiol 1991; 44:1147–57.
- 5 Rasmussen BK, Jensen R, Olesen J. Impact of headache on sickness absence and utilisation of medical services: a Danish population study. J Epidemiol Community Health 1992; 46:443–6.
- 6 Ward TN. Medication overuse headache. Prim Care 2004; 31:369–80, vii.
- 7 Diener HC, Dichgans J, Scholz E, Gerselhart S, Gerber WD, Biile A. Analgesic-induced chronic daily headache:

- long-term results of withdrawal therapy. *J Neurol* 1989; 236:9–14.
- 8 Glass DE. Tension headache and some psychiatric aspects of headache. *Headache* 1992; 3:262–98.
  - 9 Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. *Pain* 1993; 53:65–72.
  - 10 Raja SN, Williams S, McGee R. Multidimensional health locus of control beliefs and psychological health for a sample of mothers. *Soc Sci Med* 1994; 39:213–20.
  - 11 Bendtsen L. Sensitization: its role in primary headache. *Curr Opin Investig Drugs* 2002; 3:449–53 (Review).
  - 12 Holroyd KA. Behavioral and psychologic aspects of the pathophysiology and management of tension-type headache. *Curr Pain Headache Rep* 2002; 6:401–7 (Review).
  - 13 Jensen R. Peripheral and central mechanisms in tension-type headache: an update. *Cephalalgia* 2003; 23 (Suppl. 1):49–52 (Review).
  - 14 Sharff L, Turk DC, Marcus DA. The relationship of locus of control and psychosocial behavioral response in chronic headache. *Headache* 1995; 35:527–33.
  - 15 Jull GA. Deep cervical neck flexor dysfunction in whiplash. *J Musculoskeletal Pain* 2000; 8:143–54.
  - 16 Bertolotti G, Vidotto G, Sanavio E, Frediani F. Psychological and emotional aspects and pain. *Neurol Sci* 2003; 24 (Suppl. 2):S71–5.
  - 17 Schoenen J. Treatment of tension headache. *Rev Neurol* 2000; 156 (Suppl. 4):4S, 87–92 (Review) [in French].
  - 18 Vernon H, McDermaid C, Hagino C. Systematic review of randomized clinical trials of complementary/alternative therapies in the treatment of tension-type and cervicogenic headache. *Comp Ther Med* 1999; 7:142–55.
  - 19 Pollmann W, Keidel M, Pfaffenrath V. Headache and the cervical spine: a critical review. *Cephalalgia* 1997; 17:801–16.
  - 20 Olesen J. Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs. *Pain* 1991; 46:125–32.
  - 21 Falla DL, Campbell CD, Fagan AE, Thompson DC, Jull GA. Relationship between cranio-cervical flexion range of motion and pressure change during the cranio-cervical flexion test. *Man Ther* 2003; 8:92–6.
  - 22 Jull G, Barrett C, Magee R, Ho P. Further characterization of muscle dysfunction in cervical headache. *Cephalalgia* 1999; 19:179–85.
  - 23 Jull G, Trott P, Potter H, Zito G, Niere K, Shirley D et al. A randomized controlled trial of exercise and manipulative therapy for cervicogenic headache. *Spine* 2002; 27:1835–43.
  - 24 Vandenheede M, Schoenen J. Central mechanism in tension-type headache. *Curr Pain Headache Dep* 2002; 6:392–400 (Review).
  - 25 Christensen M, Bendtsen L, Ashine M, Jensen R. Experimental induction of muscle tenderness and headache in tension-type headache patients. *Cephalalgia* 2005; 25:1061–7.
  - 26 International Headache Committee on Clinical Trials. Guidelines for trials of drug treatment in tension-type headache. *Cephalalgia* 1995; 15:165–79.
  - 27 Maitland GD. *Vertebral manipulation*, 5th edn. Sydney: Butterworths 1986.
  - 28 Falla D, Rainoldi A, Merletti R, Jull G. Myoelectric manifestations of sternocleidomastoid and anterior scalene muscle fatigue in chronic neck pain patients. *Clin Neurophysiol* 2003; 114:488–95.
  - 29 Watson DH, Trott PH. An investigation of natural head posture and upper cervical flexor muscle performance. *Cephalalgia* 1993; 13:272–84.
  - 30 Bendtsen L. Central and peripheral sensitization in tension-type headache. *Curr Pain Headache Rep* 2003; 7:460–5.
  - 31 Mayoux Benhamou MA, Revel M, Vallee C, Roudier R, Barbet JP, Bary F. Longus colli has a postural function on cervical curvature. *Surg Radiol Anat* 1994; 16:367–71.
  - 32 Jensen MP, Turner JA, Romano JM. What is the maximum number of levels needed in pain intensity measurement? *Pain* 1994; 58:387–92.
  - 33 Ferrell BA, Ferrell BR, Rivera L. Pain in cognitively impaired nursing home patients. *J Pain Symptom Manage* 1995; 10:591–8.
  - 34 Faul F, Erdfelder E. *GPOWER: a priori, post-hoc, and compromise power analysis*. Bonn: Department of Psychology, Bonn University 1992.
  - 35 Manz BD, Mosier R, Nusser-Gerlach MA, Bergstrom N, Agrawal S. Pain assessment in the cognitively impaired and unimpaired elderly. *Pain Manage Nurs* 2000; 1:106–15.
  - 36 Wynne CF, Ling SM, Remsburg R. Comparison of pain assessment instruments in cognitively intact and cognitively impaired nursing home residents. *Geriatr Nurs* 2000; 1:20–3.
  - 37 Van der Zee KI, Sandeman R, Heyink J. Psychometric quality of the MOS 36-item Short-Form Health Survey (SF-36) in a Dutch population. *Tijdschr Sociale Gezondheidszorg* 1993; 7:183–91 [in Dutch].
  - 38 Guitera V, Munoz P, Castillo J, Pascual J. Quality of life in chronic daily headache: a study in a general population. *Neurology* 2002; 58:1062–5.
  - 39 Monzon MJ, Lainez MJ. Quality of life in migraine and chronic daily headache patients. *Cephalalgia* 1998; 18:638–43.
  - 40 Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcome Study. *Med Care* 1995; 33 (4 Suppl.):AS264–79.
  - 41 Van der Heijden PG, van Buuren S, Fekkes M, Radder J, Verrips E. Unidimensionality and reliability under Mokken scaling of the Dutch language version of the SF-36. *Qual Life Res* 2003; 12:189–98.
  - 42 Martin NJ, Holroyd KA, Penzier DB. The Headache-Specific Locus of Control Scale: adaption to recurrent headaches. *Headache* 1990; 30:729–34.
  - 43 Martin NJ, Holroyd KA, Rokicki LA. The Headache Self Efficacy Scale: adaption to recurrent headaches. *Headache* 1993; 33:244–8.
  - 44 Cohen J. *Statistical power analysis for the behavioral sciences*. London: Academic Press 1977.
  - 45 Makowska A, Panfil C, Ellrich J. Long-term potentiation of orofacial sensorimotor processing by noxious input

- from the semispinal neck muscle in mice. *Cephalalgia* 2005; 25:109–16.
- 46 Zanchin G, Maggioni F, Granella F, Rossi P, Falco L, Manzoni GC. Self-administered pain-relieving manoeuvres in primary headache. *Cephalalgia* 2001; 21:718–26.
- 47 Lenssinck ML, Damen L, Verhagen AP, Berger MY, Passchier J, Koes BW. The effectiveness of physiotherapy and manipulation in patients with tension-type headache: a systematic review. *Pain* 2004; 112:381–8.
- 48 Bronfort G, Nilsson N, Haas M, Evans R, Goldsmith CH, Assendelft WJ, Bouter LM. Non-invasive physical treatments for chronic/recurrent headache. *Cochrane Database Syst Rev* 2004; CD001878.
- 49 Biondi DM. Physical treatments for headache: a structured review. *Headache* 2005; 45:738–46.